ARTICLE | Clinical News
TK54 regulatory update
October 25, 2010 7:00 AM UTC
The European Commission granted Orphan Drug designation for LTKfarma's TK54 to treat acute myelogenous leukemia (AML). LTKfarma plans to start Phase I/II testing for the indication in late 2011. The p...